+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06607276

Phase 2 Study of Adebrelimab Combined With Capecitabine as Post-Surgery Treatment for High-Risk Cholangiocarcinoma

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2025-01-16

122

Participants Needed

4

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Cholangiocarcinoma is a cancer that originates in the bile ducts, and its main treatment is surgical removal of the tumor. Despite advances in imaging and surgical techniques, the rate of successful surgery and long-term survival remain low due to high recurrence after surgery. This trial investigates whether adding the drug Adebrelimab combined with capecitabine as a postoperative treatment can improve outcomes in patients with high-risk resected cholangiocarcinoma. Participants will be randomly assigned to one of two groups one receiving Adebrelimab plus capecitabine and the other receiving capecitabine alone. Adebrelimab is given intravenously every three weeks at a dose of 1200 mg for one year. Capecitabine is taken orally twice daily on days 1 to 14 of a 21-day cycle for 6 to 8 cycles. This study is open-label and multicenter, focusing on comparing the safety and effectiveness of these treatment approaches after surgery. During the study, participants will undergo regular assessments including imaging to check for tumor recurrence, laboratory tests, and monitoring for side effects. The primary goal is to measure the rate of recurrence-free survival one year after treatment begins. Secondary outcomes include overall survival over three years, recurrence-free survival over two years, and minimal residual disease monitoring. The total study duration includes all treatment cycles and follow-up assessments up to three years to evaluate long-term effects and safety.

CONDITIONS

Brief Title

Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE

Research Team

X

Xiangcheng Li, Prof. M.D.

C

Changxian Li, Prof. M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here